May 2000
Worldwide Biotech;May2000, Vol. 12 Issue 5, p2
Trade Publication
Announces the worldwide license received by Gilead Sciences Inc. and EyeTech Pharmaceuticals Inc. for its investigational therapy for age-related macular degeneration.


Related Articles

  • Injection approved for macular degeneration.  // Drug Topics;1/10/2005, Vol. 149 Issue 1, p8 

    Reports on the approval of Pegaptanib sodium injection 0.3 mg from Eyetech Pharmaceuticals/Pfizer, for the treatment of neovascular age-related macular degeneration.

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • Changes in pegaptanib labeling prompted by adverse reactions. Charters, Lynda // Ophthalmology Times;5/15/2006, Vol. 31 Issue 10, p8 

    The article focuses on the changes in the product labeling for pegaptanib sodium injection made by OSI Pharmaceuticals Inc., Eyetech Pharmaceuticals Inc. and Pfizer Inc. The injection was approved by the United States Food and Drug Administration for the treatment of neovascular age-related...

  • At OSI, a $935M poke in the Eye(tech). Harrell, Jeremy // Long Island Business News (7/1993 to 5/2009);11/10/2006, Vol. 53 Issue 51, p5A 

    The article reports developments surrounding the $935-million investment in cash and stock of OSI Pharmaceuticals Inc. to acquire the macular degeneration drug called Macugen from Eyetech Pharmaceuticals Inc. in Melville, New York in November 2005. At that time, analysts and stockholders...

  • Macugen account goes to Medicus. Arnold, Matthew // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p10 

    Reports that Pfizer and Eyetech Pharmaceuticals have appointed Medicus New York to handle professional advertising for their co-marketed Macugen drug for macular degeneration. Account is Medicus Group's first formal assignment from Pfizer; Parent firm Publicis Groupe's work with Pfizer in the...

  • Retina Specialists: A Grim View of AMD.  // Review of Ophthalmology;Aug2004, Vol. 11 Issue 8, p12 

    Presents results from the online survey regarding wet age-related macular degeneration (AMD), commissioned by the Eyetech Pharmaceuticals and Pfizer, in consultation with the Lighthouse International. Percentage of specialists who were alarmed by the increasing number of cases of wet AMD; Effect...

  • AMD: A Revolution In Therapy Begins. Rosenfeld, Philip // Review of Ophthalmology;Mar2005, Vol. 12 Issue 3, p96 

    Assesses the effectiveness of Macugen, an ophthalmic drug from Eyetech Pharmaceuticals Inc. and Pfizer Inc., that specifically targets the vascular endothelial growth factor (VEGF) to treat age-related macular degeneration. Correlation between elevated levels of VEGF and various diseases that...

  • Eyetech aims to be retina specialists' biotech resource. Dlugoss, Mark L. // Ophthalmology Times;6/1/2005, Vol. 30 Issue 11, p3 

    Reports on the projects being explored by New York-based Eyetech Pharmaceuticals to deliver medical solutions for the betterment of patients who suffer from blinding eye diseases. Implication of the U.S. Food and Drug Administration's approval of Eyetech's pegaptanib sodium injection product for...

  • Priority review for Pfizer, Eyetech AMD drug.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p11 

    The article reports that Macugen, a treatment for age-related macular degeneration jointly developed by Pfizer Corp. and Eyetech Pharmaceuticals Inc. has been granted a priority review designation by the U.S.Food and Drug Administration (FDA). The companies submitted the final portion of the new...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics